Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Xiamen Translational Medical Key Laboratory of Hepatobiliary and Pancreatic Tumor, Zhongshan Hospital, Xiamen University, Xiamen 361004, People's Republic of China.
Nanotechnology. 2017 Nov 3;28(44):445101. doi: 10.1088/1361-6528/aa8791. Epub 2017 Aug 22.
Postoperative recurrence and metastasis are the major problems for the current treatment of hepatocellular carcinomas (HCC) in the clinic, including hepatectomy and liver transplantation. Here, we report that arsentic-loaded nanoparticles (ALNPs) are able to reduce the invasion of HCC cells in vitro, and, more importantly, can strongly suppress the invasion and metastasis of HCC in vivo without adverse side effects. Compared to free drug arsenic trioxide , ALNPs can deliver the drug into cancer cells more efficiently, destroy the structure of microtubules and reduce the aggregation of microfilaments in cell membranes more significantly. Furthermore, our results also reveal that tumor cells in murine blood were reduced remarkably after intravenous injection of ALNPs, indicating that this nano-drug may efficiently kill circulating tumor cells in vivo. In conclusion, our nano-drug ALNPs have great potential for the suppression of metastasis of HCC, which may open up a new avenue for the effective treatment of HCC without metastasis and recurrence.
术后复发和转移是目前肝癌（HCC）临床治疗中肝切除术和肝移植的主要问题。在这里，我们报告载砷纳米粒子（ALNPs）能够减少 HCC 细胞的体外侵袭，更重要的是，能够在没有不良反应的情况下强烈抑制 HCC 的体内侵袭和转移。与游离药物三氧化二砷相比，ALNPs 能够更有效地将药物递送到癌细胞中，更显著地破坏微管结构并减少细胞膜中微丝的聚集。此外，我们的结果还表明，静脉注射 ALNPs 后，小鼠血液中的肿瘤细胞明显减少，这表明这种纳米药物可能在体内有效地杀死循环肿瘤细胞。总之，我们的纳米药物 ALNPs 在抑制 HCC 转移方面具有很大的潜力，这可能为有效治疗无转移和无复发的 HCC 开辟新的途径。
